About Lifordi Immunotherapeutics, Inc.

This company develops antibody-drug conjugates (ADCs) that precisely target and treat autoimmune and inflammatory diseases. Their proprietary ADC platform aims to deliver enhanced efficacy and safety, creating innovative therapies for unmet needs in immunology and inflammation.

```xml <problem> Current treatments for autoimmune and inflammatory diseases often lack precise targeting, leading to systemic toxicity and reduced efficacy. This results in significant unmet needs across various medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology. </problem> <solution> Lifordi Immunotherapeutics is developing novel therapies for autoimmune and inflammatory disorders using a targeted antibody-drug conjugate (ADC) platform. Their approach leverages the success of ADCs in oncology by directing potent immunosuppressive agents specifically to immune cells, including myeloid and lymphoid cells. The platform targets a cell surface protein, VISTA, which exhibits rapid internalization and intracellular accumulation, making it ideal for ADC-based delivery. Preclinical studies of Lifordi's lead ADC candidate, LFD-200, have demonstrated a short serum half-life and long immune cell residency, resulting in extended immunosuppressive function within these cells without systemic toxicity. </solution> <features> - ADC-based delivery platform targeting a cell surface protein (VISTA) expressed on immune cells - Rapid internalization and intracellular accumulation of the ADC within target cells - LFD-200, a lead ADC candidate, demonstrates short serum half-life and long immune cell residency - Ability to exert immunosuppressive function within immune cells for an extended duration - Reduced systemic toxicity compared to traditional systemic delivery methods - Applicable to various payloads, including small molecules and nucleic acids - Potential application across multiple autoimmune and inflammatory conditions in rheumatology, gastroenterology, pulmonology, and dermatology </features> <target_audience> The primary target audience includes patients suffering from autoimmune and inflammatory disorders, as well as pharmaceutical companies seeking innovative and targeted therapeutic approaches in immunology. </target_audience> ```

What does Lifordi Immunotherapeutics, Inc. do?

Where is Lifordi Immunotherapeutics, Inc. located?

Lifordi Immunotherapeutics, Inc. is based in Burlington, Canada.

When was Lifordi Immunotherapeutics, Inc. founded?

Lifordi Immunotherapeutics, Inc. was founded in 2023.

Location

Burlington, Canada

Founded

2023

Employees

21 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Lifordi Immunotherapeutics, Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

lifordi.com 700+

Founded 2023 – Burlington, Canada

Funding

No funding information available.

Team (20+)

No team information available.

Company Description

Problem

Current treatments for autoimmune and inflammatory diseases often lack precise targeting, leading to systemic toxicity and reduced efficacy. This results in significant unmet needs across various medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology.

Solution

Lifordi Immunotherapeutics is developing novel therapies for autoimmune and inflammatory disorders using a targeted antibody-drug conjugate (ADC) platform. Their approach leverages the success of ADCs in oncology by directing potent immunosuppressive agents specifically to immune cells, including myeloid and lymphoid cells. The platform targets a cell surface protein, VISTA, which exhibits rapid internalization and intracellular accumulation, making it ideal for ADC-based delivery. Preclinical studies of Lifordi's lead ADC candidate, LFD-200, have demonstrated a short serum half-life and long immune cell residency, resulting in extended immunosuppressive function within these cells without systemic toxicity.

Features

ADC-based delivery platform targeting a cell surface protein (VISTA) expressed on immune cells

Rapid internalization and intracellular accumulation of the ADC within target cells

LFD-200, a lead ADC candidate, demonstrates short serum half-life and long immune cell residency

Ability to exert immunosuppressive function within immune cells for an extended duration

Reduced systemic toxicity compared to traditional systemic delivery methods

Applicable to various payloads, including small molecules and nucleic acids

Potential application across multiple autoimmune and inflammatory conditions in rheumatology, gastroenterology, pulmonology, and dermatology

Target Audience

The primary target audience includes patients suffering from autoimmune and inflammatory disorders, as well as pharmaceutical companies seeking innovative and targeted therapeutic approaches in immunology.